Epkinly
epcoritamab
APPROVED
Drug Profile
ModalityBispecific
RouteSC
Therapy AreaOncology
Launch2023-05-19
US LOE2035-05-19
Peak Sales Est$3000M
Formulations[{"id":"epkinly-sc","route":"SC","setting":"OUTPATIENT","frequency":"Weekly then Q2W then Q4W","is_p
Mechanism: CD20xCD3 bispecific
Expert: Bispecific T-cell engager binding CD20 on B-cells and CD3 on T-cells, inducing T-cell mediated cytotoxicity.
Everyday: A protein that helps immune cells find and kill lymphoma cells.
Targets: ["CD20","CD3"]
Revenue History
| Period | Revenue ($M) |
|---|
| 2025 | $271M |
| Q4 2025 | $95M |
Programs (5)
| Indication | Stage | Key Study | Regional Status |
|---|
| R/R FL | APPROVED | EPCORE NHL-1 | [{"stage":"APPROVED","region":"US","approval_date":"2024-02-01"}] |
| 1L DLBCL | PHASE3 | EPCORE DLBCL-2 | [] |
| R/R DLBCL | APPROVED | EPCORE NHL-1 | [{"stage":"APPROVED","region":"US","approval_date":"2023-05-19"},{"stage":"APPRO |
| R/R FL | APPROVED | EPCORE FL-1 | [{"stage":"APPROVED","region":"US","approval_date":"2024-12-20"}] |
| 2L DLBCL TI | PHASE3 | EPCORE DLBCL-4 | [] |
Upcoming Catalysts (4)
Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-4)
H1 2026
Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-2)
H2 2026
Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-2)
H2 2026
Epkinly - DLBCL - Ph3 - Topline (EPCORE DLBCL-4)
H2 2026
Notes
SC CD20xCD3 T-cell engager. Co-developed with Genmab. Approved for R/R DLBCL (3L+) and R/R FL. 2025 revenue $271M. Ph3 ongoing in 2L DLBCL, 1L DLBCL.
Data from Supabase · Updated 2026-03-24